Lipella Pharmaceuticals Bolsa (OTC: LIPO)

Últimas noticias sobre Lipella Pharmaceuticals (OTC:LIPO) Bolsa

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Emmanuel Rosner downgraded the rating for Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Outperform to Peer Perform. Aptiv shares closed at $71.67 on Tuesday. <a href="https://www.benzinga.com/quote/aptv/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Andrew Boone downgraded CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) from Market Outperform to Market Perform and maintained the price target of $38. CarGurus shares closed at $33.74 on Tuesday. <a href="https://www.benzinga.com/quote/carg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Froylan Mendez downgraded Arcos Dorados Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) from Overweight to Neutral and lowered the price target from $10.5 to $8.8. Arcos Dorados shares closed at $7.97 on Tuesday. <a href="https://www.benzinga.com/quote/arco/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst A.J. Rice downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Neutral and lowered the price target from $80 to $45. Centene shares closed at $56.65 on Tuesday. <a href="https://www.benzinga.com/quote/cnc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andrew Rosivach downgraded Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Outperform to Peer Perform. Textron shares closed at $56.69 on Tuesday. <a href="https://www.benzinga.com/quote/iipr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CNC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/cnc/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02082713/image-26-1024x564.png" alt="" class="wp-image-970308" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02082713/image-26-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02082713/image-26-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02082713/image-26-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02082713/image-26.png 1163w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46216643/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

News

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

APTV

ARCO

CARG

IIPR

This Centene Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Stephens &amp; Co. analyst Tommy Moll maintains MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) with a Equal-Weight and raises the price target from $85 to $90.

Price Target

Stephens & Co. Maintains Equal-Weight on MSC Industrial Direct Co, Raises Price Target to $90

<a href="https://www.bloomberg.com/news/articles/2025-07-02/house-republican-hardliners-warn-of-a-delay-to-trump-tax-vote?srnd=homepage-americas&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-07-02/house-republican-hardliners-warn-of-a-delay-to-trump-tax-vote?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-02/house-republican-hardliners-warn-of-a-delay-to-trump-tax-vote?srnd=homepage-americas&amp;embedded-checkout=true</a>

Government

Politics

General

'House Republican Hardliners Warn Of A Delay To Tax Vote' - Bloomberg

Treasury Secretary Scott Bessent commented on the ongoing feud between Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Elon Musk and President Donald Trump, suggesting that the conflict is unlikely to affect the passing of a significant bill.
What Happened: In a recent interview with&nbsp;Fox News, Bessent touched on the Musk-Trump clash. &#8220;I think if Elon sticks to rockets, I will stick to finance,&#8221; he remarked, suggesting that each should concentrate on their respective domains.
Bessent also voiced his support for a bill aimed at reducing the national debt, which recently cleared the Senate thanks to a tie-breaking vote by Vice President JD Vance. &#8220;I am confident that this bill is going to pay down the debt and there were 50 senators who weren&#8217;t threatened by his words,&#8221; he declared.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Sec Bessent: If Elon &#039;sticks to rockets,&#039; I&#039;ll stick to finance" width="500" height="281" src="https://www.youtube.com/embed/KFG0vefELtg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The finance expert lauded President Trump&#8217;s leadership, alongside Leader Thune and Speaker Mike Johnson, in propelling the bill. He is confident they will unite majorities and push the legislation forward. &#8220;I think everyone is with President Trump and his leadership going to move this forward more than anybody&#8217;s checkbook,&#8221; Bessent concluded.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no" target="_blank" rel="noreferrer noopener">Trump Says Elon Musk Would &#8216;Close Up Shop And Head Back Home To South Africa&#8217; Without Subsidies: &#8216;No More Rocket Launches, Satellites, Or Electric Car&#8217;</a>
Why It Matters: The ongoing feud between Musk and Trump has been a topic of concern for many, especially as it could potentially impact Tesla&#8217;s future. As&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46215572/as-tesla-slides-below-1-trillion-analyst-warns-musk-trump-rift-could-undermine-autonomy-push-it-doesnt-make-any-sense-for-elon-to-be-fighting-with-donald-trump">Tesla&#8217;s stock struggles</a>&nbsp;to regain its footing, analysts have warned that the rift could complicate the company&#8217;s push into autonomous vehicle regulation.
Despite this, Bessent&#8217;s comments suggest that the feud may not have a significant impact on the passing of a crucial bill. The bill, which encompasses tax cuts, reductions in social safety net programs, and increased spending on the armed forces and immigration enforcement, has been a point of contention. It was&nbsp;<a href="https://www.benzinga.com/news/politics/25/07/46211326/one-big-beautiful-bill-passes-senate-with-jd-vances-tie-breaking-vote-trump-says-its-going-to-go-very-nicely-in-the-house">narrowly passed by the Senate</a>&nbsp;and is now set to move to the House of Representatives for potential final approval.
Despite opposition from some Republicans, Trump aims to sign it into law by the July 4 holiday. This bill&#8217;s passing could have significant implications for the country&#8217;s financial future, and Bessent&#8217;s comments suggest that the feud between Musk and Trump may not be enough to derail its progress.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46186509/scott-bessent-on-replacing-powell-as-fed-chair-i-will-do-what-the-president-wants-plays-down-shadow-chair-speculations">Scott Bessent On Replacing Powell As Fed Chair: &#8216;I Will Do What The President Wants&#8217; — Plays Down Shadow Chair Speculations</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Scott Bessent Says Senators Not 'Threatened' By Elon Musk's Words, Bill Advancing Under Trump's Leadership 'More Than Anybody's Checkbook'

Barclays analyst Andrew Mok initiates coverage on Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) with a Equal-Weight rating and announces Price Target of $5.5.

Initiation

AVAH

Barclays Initiates Coverage On Aveanna Healthcare Hldgs with Equal-Weight Rating, Announces Price Target of $5.5

Financial analyst Gary Black, the managing partner at the Future Fund LLC, has issued a bold take on the U.S. fiscal health, likening the nation's debt to corporate debt levels and calling it &#8220;fairly low.&#8221;
What Happened: In a post on X, Black argued that the U.S. debt-to-GDP ratio of 125%, following a $3.3 trillion increase from a recent tax and spending bill, namely the One Big Beautiful Bill Act, remains &#8220;fairly low&#8221; compared to Japan's 240%.
The bill, <a href="https://www.benzinga.com/news/politics/25/07/46211326/one-big-beautiful-bill-passes-senate-with-jd-vances-tie-breaking-vote-trump-says-its-going-to-go-very-nicely-in-the-house">approved 51-50 by the Senate</a> with VP JD Vance's deciding vote, is expected to pass the House before the weekend.
Black framed the debt-to-GDP ratio as akin to a company's debt-to-income level, noting its stability since 2020 despite post-war and recessionary spikes.
He dismissed concerns from ultra-conservatives about deficit spending adding to the $36 trillion national debt, suggesting a more reliable gauge of financial health is the U.S.'s AA+ credit rating with a stable outlook, as affirmed by S&amp;P, Moody's, and DBRS.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">2/ Some ultra conservatives have a view that any deficit spending is unhealthy, since it increases the U.S. debt (currently $36T). Most economists look at U.S. debt relative to U.S. GDP, and a $3.3T increase in the U.S. debt translates to a still fairly low debt-to-GDP ratio of…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1940347944923721824?ref_src=twsrc%5Etfw">July 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Elon Musk warned on June 18 in an X post that the U.S. is nearing &#8220;de facto bankruptcy&#8221; as <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45988656/elon-musk-warns-us-faces-de-facto-bankruptcy-if-37-trillion-debt-not-tackled-peter-schiff-says-we-are-already-bankrupt">federal debt exceeds $37 trillion</a>. He highlighted that interest payments on this debt now consume 25% of all tax revenue. Quoting &#8220;Wall Street Mav,&#8221; Musk stated that if this trend persists, all tax revenue will eventually be used to service the national debt, leaving &#8220;nothing left for anything else.&#8221;
See Also: <a href="https://www.benzinga.com/news/politics/25/07/46213361/trump-is-slamming-jerome-powell-because-he-wants-a-weaker-dollar-says-ed-yardeni-pounding-powell-po">Trump Is Slamming Jerome Powell Becauspe He &#8216;Wants A Weaker Dollar,&#8217; Says Ed Yardeni: &#8216;Pounding Powell = Pounding The Dollar&#8217;</a>
Why It Matters: Billionaire Ray Dalio, on the other hand, has been a staunch critic of increasing government debt.
In a recent X post on Monday, Dalio proposed <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46186853/ray-dalio-says-politicians-that-promise-not-to-raise-your-taxes-not-aligned-with-preventing-a-big-debt-dollar-crisis-to-me-thats-a-tragedy">increasing taxes instead of slashing them</a> to control the deficit problem. "There is no way that the deficit/debt bomb problem can be sustainably dealt with unless there is a mix of tax revenue increases and spending decreases that are determined in a bipartisan way," the founder of Bridgewater Associates said. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;I promise to not raise your taxes&quot; and &quot;I promise to not cut your benefits&quot; are the two popular political promises that are inconsistent with the much more needed promise &quot;I promise to cut the budget deficit to about 3 percent of GDP&quot; that is required to prevent a big…
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1939835947236966609?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Contrary to Black&#8217;s point on credit rating agencies, <a href="https://www.benzinga.com/general/market-summary/25/05/45512063/ray-dalio-warns-against-decreasing-value-of-us-dollar-amid-mounting-government-debt-risks-are-greater-than-the-rating-agencies-are-conveying">Dalio has called out</a> the role of such agencies, stating that "credit ratings understate credit risks," as they only consider the probability of default and the loss given a default by the government. 
"Said differently, for those who care about the value of their money, the risks for U.S. government debt are greater than the rating agencies are conveying," he argued.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, edged slightly higher on Wednesday. The SPY was up 0.11% at $618.32, while the QQQ advanced 0.013% to $547.06, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46188237/bill-gates-is-betting-two-thirds-of-his-foundations-portfolio-in-these-3-stocks" target="_blank" rel="noreferrer noopener">Bill Gates Is Betting Two-Thirds Of His Foundation's Portfolio In These 3 Stocks</a> </li>
</ul>
Photo: Jonathan Weiss/Shutterstock

Gary Black Counterns Elon Musk's Bankruptcy Warning, Says US Debt 'Fairly Low' At 125% Of GDP

Barclays analyst Andrew Mok initiates coverage on Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) with a Underweight rating and announces Price Target of $17.

OSCR

Barclays Initiates Coverage On Oscar Health with Underweight Rating, Announces Price Target of $17

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) fell sharply in today's pre-market trading after the health<a href="https://www.benzinga.com/quote/CNC"> care company withdrew its guidance for 2025.</a>
Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company's preliminary interpretation of marketplace data from the independent actuarial firm Wakely.
Centene shares dipped 27.7% to $40.94 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) tumbled 9% to $278.89 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.8% to $15.37 in pre-market trading after the company lowered its FY25 revenue guidance from $2.75–$2.84 billion to $2.68–$2.73 billion.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 8.3% to $18.75 in pre-market trading after dipping 5% on Tuesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $11.22 in pre-market trading. Mesoblast shares gained 11% on Tuesday after the company announced it is targeting an accelerated FDA approval for its heart failure drug Revascor.</li>
<li>ArriVent BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) fell 5.4% to $19.76 in pre-market trading as the company announced the pricing of $75 million public offering of common stock and pre-funded warrants.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 4.6% to $20.05 in pre-market trading after the company announced plans for a $100 million convertible notes offering.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a></li>
</ul>
Photo via Shutterstock

Markets

Movers

AVBP

DFDV

MESO

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Emmanuel Korch upgraded the rating for Visteon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Peer Perform to Outperform. Visteon shares closed at $98.77 on Tuesday. <a href="https://www.benzinga.com/quote/VC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Katie Lachapelle upgraded Energy Fuels Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) from Speculative Buy to Buy and raised the price target from C$9.5 to C$9.75. <a href="https://www.benzinga.com/quote/UUUU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Corey Tarlowe upgraded the rating for Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Hold to Buy and raised the price target from $135 to $150. Ross Stores shares closed at $129.97 on Tuesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ROST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ROST/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02081557/image-25-1024x579.png" alt="" class="wp-image-970284" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02081557/image-25-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02081557/image-25-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02081557/image-25-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02081557/image-25.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46216643/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Upgrades

ROST

UUUU

This Ross Stores Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday

WIIM

CIFR

Cipher Mining shares are trading higher after the company announced updates on the self-mining hashrate capacity for Phase 1 of Black Pearl.

UBS analyst Steven Fisher downgrades KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) from Buy to Neutral and lowers the price target from $66 to $54.

UBS Downgrades KBR to Neutral, Lowers Price Target to $54

BlueForge Alliance and Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) on Wednesday <a href="https://www.benzinga.com/pressreleases/25/07/b46216033/blueforge-alliance-and-palantir-launch-warp-speed-for-warships-to-digitally-transform-the-u-s-mari">announced the launch</a> of &#8220;Warp Speed for Warships,&#8221; a new initiative aimed at modernizing the U.S. Navy&#8217;s shipbuilding efforts through digital transformation and faster production timelines.
The project, funded by the Navy&#8217;s Maritime Industrial Base (MIB) Program, builds on the existing partnership between the nonprofit defense integrator and Palantir. Its goal is to strengthen national maritime capabilities by streamlining collaboration among shipbuilders, suppliers, and key defense partners.
The program utilizes Palantir&#8217;s Warp Speed operating system, built on its Foundry platform, to connect stakeholders in real time, enhance supply chain visibility, and reduce bottlenecks across the defense manufacturing network. Coupled with BlueForge&#8217;s expertise in embedded manufacturing, the initiative aims to accelerate delivery and improve production readiness.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46166236/palantir-accenture-partner-to-infuse-ai-into-federal-agency-workflows" target="_blank" rel="noreferrer noopener">Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows</a>
&#8220;Our strategic partnership with Palantir is about moving with urgency and precision, equipping America&#8217;s industrial base with the tools it needs to meet unprecedented demand,&#8221; said Kiley Wren, co-founder and co-CEO of BlueForge Alliance.
Mike Gallagher, Head of Defense at Palantir, described the collaboration as a critical step in maintaining U.S. maritime superiority and providing shipbuilders with the tools to ensure strategic advantage and peace.
General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) and Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) are among the companies likely to benefit from this initiative. Additionally, defense-oriented ETFs such as the iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) and SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) could see increased relevance as the program develops.
As Palantir launches its Navy modernization effort with BlueForge, a senior executive <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46189000/palantir-is-building-the-next-aws-says-top-exec-urges-startups-to-build-on-pltr-to-tackle-more-valuable-problems-than-amazon-solved" rel="noreferrer noopener">compared</a> the company to the next Amazon Web Services. He argued Palantir&#8217;s platform solves core enterprise challenges, letting startups build advanced tools without reinventing infrastructure.
Price Action: PLTR shares are trading higher by 0.08% at $130.79 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46214540/palmer-luckey-peter-thiel-joe-lonsdale-launch-erebor-bank-for-startups-crypto-and-defense-a-digital-only-bet-on-the-post-svb-era-report" target="_blank" rel="noreferrer noopener">Palmer Luckey, Peter Thiel, Joe Lonsdale Launch Erebor Bank For Startups, Crypto And Defense — A Digital-Only Bet On The Post-SVB Era: Report</a></li>
</ul>
Image via Shutterstock

Tech

iShares Dow Jones US Aerospace & Defense Index Fund

PLTR

Palantir's Tech To Supercharge US Navy Shipbuilding

UBS analyst Faham Baig upgrades Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) from Sell to Neutral and raises the price target from $47 to $59.

UBS Upgrades Altria Group to Neutral, Raises Price Target to $59

Wallbox shares are trading lower after the company announced a 20-for-1 reverse stock split.

Management

NUWE

Nuwellis Names John Erb CEO, Effective June 27, 2025

UBS analyst A.J. Rice downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Neutral and lowers the price target from $80 to $45.

UBS Downgrades Centene to Neutral, Lowers Price Target to $45

FLYE

Fly-E Group shares are trading lower after the company announced a 1-for-5 reverse stock split.

Instil Bio shares are trading higher after the company announced it received FDA Clearance for IND of AXN-2510.

Macro Economic Events

Econ #s

Economics

USA ADP Nonfarm Employment Change (Jun) -33K Vs 99K Est

JP Morgan analyst John Stansel downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Neutral and lowers the price target from $75 to $48.

JP Morgan Downgrades Centene to Neutral, Lowers Price Target to $48

Press Releases

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Health Care

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Biotech

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Legal

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

HCTI

LIPO

LIPELLA PHARMS INC by Lipella Pharmaceuticals Inc.

Maxim Group

Comments

Lipella Pharmaceuticals

Noticias

Últimas noticias sobre Lipella Pharmaceuticals (OTC:LIPO) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL